This nucleic acid amplification panel rapidly identifies SARS-CoV-2 (COVID-19), influenza A, and influenza B from a single respiratory sample. Because clinical symptoms overlap substantially, this multiplex approach saves time and allows targeted antiviral therapy when indicated.
This test is widely used during respiratory virus season to guide treatment with antivirals such as oseltamivir or Paxlovid, support infection control decisions, and reduce unnecessary antibiotic use for viral infections. Sample type is a nasopharyngeal or nasal swab.
We are CLIA certified, the highest level of Medical industry compliance and standards.
Book an appointment